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Parkinson diseaseMitochondrial dysfunction is a prominent feature of various neurodegenerative diseases. A deeper
understanding of the remarkably dynamic nature of mitochondria, characterized by a delicate balance of
ﬁssion and fusion, has helped to fertilize a recent wave of new studies demonstrating abnormal
mitochondrial dynamics in neurodegenerative diseases. This review highlights mitochondrial dysfunction
and abnormal mitochondrial dynamics in Alzheimer disease, Parkinson disease, amyotrophic lateral
sclerosis, and Huntington disease and discusses how these abnormal mitochondrial dynamics may
contribute to mitochondrial and neuronal dysfunction. We propose that abnormal mitochondrial dynamics
represents a key common pathway that mediates or ampliﬁes mitochondrial dysfunction and neuronal
dysfunction during the course of neurodegeneration.
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Mitochondria, organelles found in virtually every eukaryotic cell,
are involved in a number of cellular functions and are essential to both
life and death. The many functions of mitochondria include, but are
certainly not limited to, 1) the production of cellular ATP, 2)
participation in the synthesis of key metabolites, 3) the regulation
of apoptosis, 4) calcium buffering, and 5) the primary source of
endogenous reactive oxygen species [1,2]. Neurons are particularly
sensitive to changes in mitochondrial function since they are
extremely energy dependent with many neuronal activities such as
synaptic transmission, axonal/dendritic transport, ion channels, and
ion pump activity being great energy-taxing processes [3]. The
maintenance of calcium homeostasis is critical for neuronal synaptic
function [4]. Synaptic mitochondria are important in calcium
clearance either by direct calcium removal or by providing ATP for
the plasma membrane Na+/Ca2+ exchanger [5], which become the
dominant players at sites where endoplasmic reticulum (ER) vesicles
are absent [6]. Additionally, as postmitotic cells with membranes
enriched in polyunsaturated fatty acid, neurons are sensitive to
oxidative stress [2]. Not surprisingly, mitochondrial injury can have
severe consequences for neuronal function and survival. On top of
these reasons, compared to other cell types, the complex morphology
of neurons leads to functional heterogeneity in neuronal segments,+1 216 368 8964.
ll rights reserved.thus translating into different energy and calcium buffering demands
that require local adaptation of metabolism and local cellular signals
interconnecting neuronal and mitochondrial activities. Indeed, mito-
chondria are highly mobile in both anterograde and retrograde
directions in neurons and can be positioned in neuronal segments
with high metabolic demands such as active growth cones and
synapses [3]. Therefore, neurons are also particularly sensitive to
changes in mitochondrial movement and distribution.
Studies in the past decade revealed that mitochondria are highly
dynamic organelles that constantly divide and fuse with each other
[7]. Depending on physiological conditions, mitochondria can form
giant tubule networks within a cell and allow rapid exchange of
mitochondrial contents or divide into individual rod-like mitochon-
drion and allow deep penetration into side short-diameter neurites
[7]. In fact, this highly dynamic balance of mitochondrial ﬁssion and
fusion not only controls mitochondrial morphology, length, size, and
number but also regulates mitochondrial function and distribution.
Therefore, it is not surprising that alterations in mitochondrial ﬁssion
and fusion signiﬁcantly impact neuronal function, and the prevalence
of neuronal disease associated with mutations in mitochondrial
ﬁssion/fusion genes underscores the important functional relation-
ship between mitochondrial dynamics and neuronal function [7]. For
example, mutations in Mfn2 are associated with Charcot-Marie-Tooth
disease 2A, a peripheral neuropathy targeting the axons of sensory
and motor neurons, and mutations in OPA1 cause autosomal
dominant optic atrophy characterized by progressive degeneration
of the optic nerve [7]. Alterations in mitochondrial dynamics are also
increasingly implicated in neurodegenerative diseases that may not
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fusion genes, and it in fact may become a common pathway
underlying mitochondrial abnormality and dysfunction and neuronal
dysfunction and degeneration in these neurodegenerative diseases
[8,9]. In this article, we will summarize the current evidence
indicating a potential involvement of abnormal mitochondrial
dynamics in Alzheimer disease, Parkinson disease, and other
neurodegenerative diseases and discuss the potential underlying
mechanisms.
2. Mitochondrial dynamics: A tightly controlled delicate balance
between ﬁssion and fusion
Mitochondria are formed by two membranes: the outer mem-
brane is permeable for ions and small molecules while the inner
membrane is almost impermeable, thus allowing the formation of an
electron gradient that is critical for mitochondrial function. Recent
studies indicate that mitochondria are dynamic organelles that
continuously change in number and morphology within a cell [7,9].
This highly dynamic phenomenon is regulated by a delicate balance
between two opposing processes: mitochondrial ﬁssion and mito-
chondrial fusion [7,9]. When mitochondria divide, both the inner and
outer membranes have to be cut and the mtDNA and other critical
mitochondrial contents redistributed to the daughter mitochondria
and mitochondrial transform into isolated, small, round organelles.
Although the precise mechanisms remain to be fully elucidated,
mitochondrial ﬁssion involves at least two proteins in mammals: A
large GTPase, dynamin-like protein 1 (DLP1, also referred to as Drp1)
and a small molecule, Fis1 [7,9]. DLP1, a member of the conserved
dynamin large GTPase superfamily that controls membrane tabula-
tion and ﬁssion, is primarily a cytosolic protein and is recruited to
punctuate spots on mitochondrial surface. Similar to dynamin, DLP1
can also oligomerize and form large complexes. It is believed that once
a ring-like complex structure is formed along the mitochondrial
surface, DLP1 uses GTP hydrolysis to constrict and twist tubule to
initiate ﬁssion [10]. Fis1 is a mitochondrial outer membrane protein
that evenly resides on the surface of mitochondria [11]. It is suggested
that Fis1 acts as a receptor to recruit DLP1 to mitochondria which
appears to be a limiting factor during ﬁssion. Mitochondrial ﬁssion
produces two spherical daughter mitochondria accompanied with
cristae and other inner structure remodeling that is not entirely clear
[7,9]. On the other hand, mitochondrial fusion is regulated by three
large GTPase proteins: Mitofusin 1 (Mfn1), Mitofusin 2 (Mfn2), and
optic atrophy protein 1 (OPA1) [7,9]. Both Mfn1 and Mfn2 are
mitochondrial transmembrane proteins localized to the outer mem-
brane and appear to play similar roles in mitochondrial fusion,
although they function independently of each other and have
different rates of GTP hydrolysis [12,13]. During mitochondrial fusion,
through interactions of their coiled-coil domains, Mfn 1 and Mfn 2
could form homo-oligomeric and hetero-oligomeric complexes, and
thus tether outer membranes of neighboring mitochondria together
[13,14]. For inner membrane fusion, it has been proposed that OPA1,
an inner membrane protein that faces intermembrane space, is
primarily involved and OPA1 requires Mfn1, but not Mfn2, to mediate
this process [12,15].
In mammalian cells, mitochondrial dynamics are sensitive to
various stimuli [7,9] and the mechanisms underlying the regulation of
mitochondrial dynamics are only beginning to become understood.
Most studies have focused on DLP1 and demonstrated that mito-
chondrial ﬁssion is regulated through post-translationalmodiﬁcations
such as the phosphorylation, sumoylation, ubiquitylation, and
nitrosylation of DLP1 [16–21]: DLP1 can be phosphorylated at least
at two sites (i.e., Ser616 and Ser637). While it is suggested that
phosphorylation at Ser616 (e.g., Ser585 in rat) by mitosis promoting
factor (MPF, also referred to as cyclin-dependent kinase 1) facilitates
mitochondria ﬁssion [16,17,21], there is still debate over the effect ofphosphorylation at Ser637 on mitochondrial ﬁssion activity with two
groups reported that DLP1 phosphorylated at Ser637 by PKA inhibits
mitochondrial ﬁssion [16,17] and its calcium-dependent dephosphor-
ylation by calcineurin promotes mitochondrial ﬁssion [22], while
another group reported that calcium-dependent phosphorylation of
this site by CaM kinase 1α induces DLP1 translocation to mitochon-
dria and enhances mitochondrial ﬁssion [23]. DLP1 can be ubiquiti-
nated, a process that is believed to facilitate its degradation [24]. On
the other hand, sumoylation of DLP1 by SUMO-1 protects DLP1 from
degradation, enlarges the stabilized DLP1 pool and facilitates the
translocation of DLP1 from cytosol to the mitochondria [18]. Most
recently, it is reported that S-nitrosylation of DLP1 activates GTPase
activity and mitochondrial ﬁssion [25].
3. Mitochondrial dysfunction and abnormal mitochondrial
dynamics in Alzheimer disease
AD is a neurodegenerative disorder of the elderly that leads to
progressive memory loss, impairments in behavior, language, visuos-
patial skills, and ultimately death. The disease is characterized by a
progressive neuronal loss and the presence of extracellular deposits of
amyloid-β (Aβ) as senile plaques and tau-containing intracellular
neuroﬁbrillary tangles in the brain. Mutations in Aβ precursor protein
(APP), presenilin 1 and 2 cause early-onset familial form AD.
Substantial data from positron emission tomography (PET) consis-
tently demonstrates a reduced cerebral metabolism in temporopar-
ietal cortices in AD [26] and an increased oxidative utilization, in
comparison with glucose utilization, is also well documented [27,28].
Damage to both the components and the structure of mitochondria as
well as increased oxidative stress are extensively reported in AD
[29,30]. The most consistent defect in mitochondrial components in
AD has been a deﬁciency in several key enzymes of oxidative
metabolism including α-ketoglutarate dehydrogenase complex
(KGDHC) and pyruvate dehydrogenase complex (PDHC), two
enzymes in the rate-limiting step of the tricarboxylic acid cycle, and
cytochrome oxidase (COX), the terminal enzyme in the mitochondrial
respiratory chain that is responsible for reducing molecular oxygen
[31–37]. Altered calcium homeostasis is also reported in AD
cytoplasmic hybrid (cybrids) made from mtDNA of AD subject
[38,39]. Sporadic mtDNA rearrangement (e.g., the common 5-kb
deletion) and many more sporadic mutations in the mtDNA control
region is signiﬁcantly increased in AD patients compared with control
cases [40–42]. High incidence of mtDNA base changes are also found
in Down's syndrome [43]. Presenilin 1 is found in mitochondria and
mutant presenilin 1 affects axonal transport of mitochondria
presumably by affecting phosphorylation of kinesin light chain
through effects on GSK3β [44]. APP is also found in mitochondria
and recent results suggest that APP accumulates exclusively in the
protein import channels of mitochondria of human AD brains but not
in age-matched controls and the levels of translocationally arrested
mitochondrial APP directly correlate with mitochondrial dysfunction
and severity of the disease [45]. Aβ localizes to mitochondria and
speciﬁcally interacts with certain mitochondrial proteins, which
potentiates mitochondrial, neuronal, and synaptic stress [46,47].
Earlier ultrastructural morphometric studies on mitochondria
revealed that AD neurons contained a signiﬁcantly lower percentage
of normal mitochondria and a signiﬁcantly higher percentage of the
mitochondria with broken cristae compared to aged-matched control
group [41]. Most interestingly, signiﬁcant changes in mitochondrial
size and number occurred in vulnerable neurons in AD [41],
suggesting that a potential change in mitochondrial dynamics may
be involved. Such a notion is further supported by the ﬁnding that
ﬁbroblasts from AD patients demonstrated abnormal mitochondrial
dynamics compared to normal healthy ﬁbroblasts from age-matched
control patients [48]. Indeed, expression levels of DLP1, OPA1, Mfn1,
and Mfn2 are signiﬁcantly reduced while Fis1 levels are increased in
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controls [49]. Because immunocytochemical studies demonstrate that
they primarily expressed in neurons, these ﬁndings thus conﬁrm a
tipped balance of mitochondrial ﬁssion and fusion in pyramidal
neurons of AD. In addition to morphological changes of mitochondria,
one likely outcome of the altered expression of these ﬁssion and
fusion proteins is abnormal mitochondrial distribution since manip-
ulations of these proteins in neurons mimicking these changes in AD
neurons all caused reduced dendritic mitochondrial coverage [49]. In
fact, this is consistent with the ﬁnding that mitochondria accumulate
in the soma and are reduced in neuronal processes in vivo in AD
pyramidal neurons [49]. Earlier studies demonstrated that exposure
of primary neurons to preaggregated Aβ25–35 induces acute impair-
ment in mitochondrial axonal transport [50] and striking mitochon-
drial fragmentation prior to neuronal demise [51], presumably
through enhanced nitric oxide (NO) production and increased S-
nitrosylated DLP1 formation which activates GTPase activity and
mitochondrial ﬁssion [25]. Indeed, increased S-nitrosylation of DLP1
is also found in AD brain tissues [25,49]. More detailed studies suggest
that overexpression of APP and the familial AD-causing APPswmutant
and treatment with ADDLs induce mitochondrial fragmentation and
abnormal distribution under conditions that no cell death occurs
[49,52], suggesting that Aβ-induced abnormal mitochondrial dynam-
ics may play important roles at early stages during the pathogenesis of
AD. In this regard, it is of interest to note that synaptic dysfunction is
one of the early and most robust correlate of AD-associated cognitive
deﬁcits and abnormal mitochondrial dynamics likely play an
important role in ADDLs-induced synaptic abnormalities because
ADDLs-induced loss of dendritic spine and PSD95 puncta correlated
with abnormal mitochondrial distribution and DLP1 overexpression,
likely through repopulation of neuronal processes with mitochondria,
preventing ADDLs-induced synaptic loss [49,53].
4. Mitochondrial dysfunction and abnormal mitochondrial
dynamics in Parkinson disease
Parkinson disease (PD) is the second most common neurodegen-
erative disease after AD. PD is characterized by the progressively
diminished ability to initiate voluntarymovement owing to the loss of
dopaminergic neurons in the substantia nigra. Genetic studies
indicated that most PD cases are sporadic, but a small fraction of PD
cases do exhibit evidence of heritability. Molecular and genetic studies
in familial PD have identiﬁed pathogenic mutations in ﬁve genes
including alpha synuclein, PINK-1, Parkin, DJ-1, and, most recently,
leucine-rich repeat kinase 2 (LRRK2) [54,55]. Compelling evidence
suggest thatmitochondrial dysfunction could represent a critical event
in the pathogenesis of PD: (1) In idiopathic PD, consistent and
signiﬁcant deﬁcits in subunits and activity of mitochondrial respira-
tory chain complex 1 was reported in the substantia nigra and blood
platelets of PD patients as well as in cybrids cell lines [56].
Accumulation of mtDNA deletions occurs in SNpc dopaminergic
neurons [57] and transfer of mtDNA from platelets of PD patients
into cells depleted of their own mtDNA causes complex I deﬁciency
[58]. (2) Complex 1 inhibitors such as MPP+ and rotenone induce a
Parkinson-like clinical syndrome in human [59,60]. (3) Several
recently identiﬁed familial PD genes are localized to and involved in
mitochondrial functions including PINK-1, Parkin, and DJ-1 [56].
Increasing evidence suggests that abnormal mitochondrial dy-
namics is involved in mitochondrial dysfunction or mediates neuronal
death in PD models. In CV1-4A cells, rotenone induces a rapid DLP1-
dependent mitochondrial fragmentation with intact internal mito-
chondrial structure which can be reversed after the removal of the
inhibitor, suggesting that mitochondrial (dys)function can elicit
reversible mitochondrial morphological changes [61]. This observa-
tion was conﬁrmed in neuronal cells in which rotenone induces rapid
mitochondrial fragmentation prior to neuronal death, and preventionof mitochondrial ﬁssion by overexpressing Mfn1 or dominant-
negative DLP1 mutant also prevented rotenone-induced neuronal
death [51]. Similarly, 6-OHDA also induces DLP1-dependent mito-
chondrial ﬁssion which precedes and mediates neuronal apoptosis
[62], suggesting that excessive mitochondrial ﬁssion might be
mediating neurotoxicity induced by complex I inhibition. Genetic
factors associated with PD also cause changes in mitochondrial
dynamics. For example, DJ-1 knockout MEFs demonstrated reduced
mitochondrial connectivity due to fragmentation which can be
rescued by overexpression of wild type human DJ-1 [63]. PINK1-
deﬁcient Drosophila demonstrated prominent mitochondrial abnor-
malities including fragmented cristae and hollow-appearing mito-
chondria or mitochondrial enlargement and disintegration which can
be rescued by Parkin overexpression [64–66], suggesting that PINK1
and Parkin converge within a single pathway related to mitochondrial
damage. More detailed genetic screening studies by manipulating
expression of mitochondrial ﬁssion/fusion proteins in PINK1-deﬁ-
cient or Parkin-deﬁcient ﬂies from several different groups suggest an
emerging consensual view that the PINK1/Parkin pathway promotes
mitochondrial ﬁssion and/or inhibits mitochondrial fusion in Droso-
phila [67–70]. Such a notion is also supported by some studies in
mammalian cells. For example, mitochondria of ﬁbroblasts from
patients carrying Parkin mutations demonstrated more branching
networks although no changes in mitochondrial length were noted
[71]. PINK1 knockdown in COS-7 cells leads to elongated mitochon-
dria which can be inhibited by DLP1 or Fis1 overexpression [70].
However, emerging evidence in mammalian cells has shown very
different effect of PINK1/Parkin on mitochondrial morphology: siRNA
knockdown of PINK1 or Parkin in HeLa cells or neuroblastoma cells
leads to mitochondrial fragmentation [69,72,73] which is coordinated
with enhanced mitochondrial turnover by autophagy [74]. DLP1
overexpression exacerbates the PINK1 deﬁciency phenotype while
DLP1 knockdown or expression of dominant-negative DLP1 mutant
rescues them [75]. Primary ﬁbroblasts from PD patients carrying
PINK1 mutations also demonstrated a fragmented mitochondria
network in a noticeable minority of cells [73,76]. Despite the
discrepancy, it is apparent that the role of these PD-associated
genes in regulating mitochondrial function and how dysregulation of
these genes resulted in PD are just beginning to be unraveled and it is
very likely that an altered mitochondrial dynamics is a common
pathogenic pathway.
5. Mitochondrial dysfunction and abnormal mitochondrial
dynamics in other neurodegenerative diseases
5.1. Amyotrophic lateral sclerosis
Human amyotrophic lateral sclerosis (ALS), also known as Lou
Gehrig's disease, is a neurodegenerative disease characterized by a
progressive and fatal degeneration of the large pyramidal neurons in
the motor cortex and associated corticospinal tracts as well as lower
motor neurons originating in the brainstem nuclei and spinal cord
anterior horn, resulting in loss of motor function, muscle atrophy, and
eventual paralysis, speech deﬁcit, and death. Apparently sporadic in
90% of cases, ALS also presents as a familial, usually autosomal
dominant, disease, 20% cases of which are due to mutations on the
SOD1 gene and it is considered to be a toxic gain of function rather
than a loss of normal SOD1 activity [77]. Biochemical studies revealed
decreased complex IV activity in the spinal cord and individual spinal
motor neurons [78,79]. Such mitochondrial defects were also found in
peripheral tissues from ALS patients [80,81]. Levels of the “common 5-
kb deletion” are also increased in the motor cortex and skeletal
muscle of ALS cases [80,82]. Consistently, respiratory deﬁcits
indicative of mitochondrial function abnormalities are widespread
and appear early in the course of the disease in mutant SOD1
transgenic mice [83]. Interestingly, a proportion of the predominantly
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patients and mutant SOD1 mice [84], which could presumably
damage mitochondrial function. Multiple lines of studies suggested
mitochondrial morphological abnormalities in ALS patients and
animal models. Earlier studies demonstrated the presence of
aggregates of mitochondria in the subsarcolemmal region of muscles
[85] and appearance of dense conglomerates of mitochondria in
anterior horn neurons of the lumbar spinal cord of ALS patients [86].
Strikingly vacuolated and dilated mitochondria with disorganized
cristae and membranes [87], presumably deriving from expansion of
the outer mitochondrial membrane and intermembrane space [88],
are present in motor neurons devoid of any apoptotic features at
asymptomatic stages of the disease in mutant SOD1 transgenic mice.
Continuous expression of G93A SOD1 mutant induces an extensive
fragmentation of mitochondrial network and cristae remodeling in
NSC-34 motoneuronal-like cells but not in N18TG2 neuroblastoma
cells or non-neuronal cells [89], suggesting that excessive mitochon-
drial ﬁssion may be involved in the selective vulnerability of
motoneuronal mitochondria to SOD1 mutation.
5.2. Huntington's disease
Huntington's disease (HD) is a genetic neurodegenerative disease
characterized by loss of capacity in movement control, cognition, and
emotional regulation due to the striatal neuronal loss caused by a CAG
repeat expansion (N35 CAGs) in the ﬁrst exon of the Huntingtin (Htt)
gene which becomes translated into long stretches of glutamines [90].
Growing evidence suggests that mitochondrial dysfunction is in-
volved in the pathogenesis of HD either directly or indirectly [91].
Positron emission tomography imaging studies have revealed
hypometabolism in the caudate, putamen, and cerebral cortex of
symptomatic HD subjects and nonsymptomatic known HD gene
carriers [92]. Signiﬁcant defects in mitochondrial respiratory
enzymes, including mitochondrial succinate dehydrogenase (SDH,
complex II) and aconitase, have been consistently reported in brain
tissues from HD patients [93]. More importantly, SDH inhibitors
including 3-nitropropionic acid and malonate cause medium spiny
neuronal loss and clinical and pathological features reminiscent of HD
in rodents and non-human primates [94,95]. mtDNA damage and
deletion were documented in HD patients and animal models [96,97].
Htt aggregates are associated with mitochondria and mutant Htt
directly impacts mitochondrial membrane potential, calcium han-
dling [98], and mitochondrial trafﬁcking in axon [99,100]. Most
recently, it is reported that mutant Htt causes mitochondrial
fragmentation, likely through the inhibition of mitochondrial fusion,
along with reduced ATP levels [101]. Remarkably, overexpression of
Mfn2 or dominant-negative DLP1 mutant not only prevents mito-
chondrial fragmentation but also restores ATP levels [101], suggesting
that mutant Htt-induced excessive mitochondrial ﬁssion mediates
mutant Htt-induced mitochondrial dysfunction (e.g., ATP levels).
More importantly, DLP1 knockdown rescues the motility defects
associated with expression of mutant Htt in a C. elegans model of HD
[101], suggesting that mutant Htt-induced excessive mitochondrial
ﬁssion also mediates neuronal dysfunction that leads to motility
deﬁcit. SDH inhibition by 3-nitropropionic acid caused excessive
mitochondrial ﬁssion and consequent neuronal death [102].
6. Abnormal mitochondrial dynamics: A common pathway
mediating mitochondrial dysfunction and neuronal dysfunction?
Despite the fact that different neuronal populations are affected in
the various neurodegenerative diseases discussed above, one com-
mon phenomenon is that abnormal mitochondrial dynamics is likely
involved in these diseases, which suggests that altered mitochondrial
dynamics may not be involved in the selective vulnerability of speciﬁc
neuronal populations, but rather may represent a common pathwaymediating or amplifying mitochondrial dysfunction and neuronal
dysfunction during the course of neurodegeneration.
6.1. Mitochondrial function
It is assumed that every mammalian cell maintains a delicate
balance of ﬁssion and fusion as reﬂected by its distinctive mitochon-
drial shape and network. Therefore, unbalanced ﬁssion or fusion will
likely have deleterious impact to mitochondrial functions. Indeed, in
addition to controlling mitochondrial number and morphology,
mitochondrial dynamics is critical for maintaining various mitochon-
drial functions: Mfn1/2-null cells and OPA1-deﬁcient cells with
excessively fragmented mitochondria demonstrate greatly reduced
endogenous and uncoupled respiratory rates which is due to
attenuation of electron transport rates in respiration complexes I, III,
and IV and demonstrated reversible interorganellar heterogeneity in
membrane potential and inhibition of cell growth [12,103]. Purkinje
cells of Mfn2 conditional knockout mouse have aberrant electron
transport chain activity [104]. Similarly, excessive fusion induced by
genetic inhibition of DLP1 causes a reduced rate of mitochondrial ATP
synthesis due to a signiﬁcant decrease in complex IV activity and an
inefﬁcient OXPHOS system [1]. Sustained elongation of mitochondria
induced by Fis1 knockdown was also associated with decreased
mitochondrial membrane potential [105]. Mitochondrial Ca2+ uptake
and intramitochondrial Ca2+ diffusion is impaired in cells with
fragmented mitochondria, suggesting an imbalance between mito-
chondrial ﬁssion and fusion can disrupt normal Ca2+ ion homeostasis
[106,107]. Recently, it was demonstrated that mitochondrial frag-
mentation mediated by the ﬁssion process is a necessary component
to increase high glucose-induced respiration and to ROS overproduc-
tion, and inhibition of mitochondrial ﬁssion prevented periodic
ﬂuctuation of ROS production during high-glucose exposure [108].
On the other hand, sustained elongation also leads to increased
reactive oxygen species production [105,109]. However, how exces-
sive ﬁssion or fusion impact mitochondrial function is not clear.
As a dynamics process, the balance between mitochondrial ﬁssion
and fusion is also sensitive to alterations in cellularmetabolism, energy
status, and redox homeostasis. In a recent report by Ichishita et al.
[110], the authors knocked down 719 genes predicted to code formost
of mitochondrial proteins. Strikingly, N80% of them caused abnormal
mitochondrial morphology, including fragmentation and elongation.
This report strongly suggests that fundamental mitochondrial func-
tions, including metabolism and oxidative phosphorylation, are
necessary for maintenance of mitochondrial tubular networks as
well as membrane ﬁssion and fusion. Consistent with this report,
inhibitors of electron transport, ATP synthase, or the permeability
transition pore (mtPTP) induced reversible mitochondrial ﬁssion [61].
Sandebring et al. [75] suggested that PINK1 deﬁciency causes
mitochondrial ﬁssion via impaired mitochondrial membrane poten-
tial. Indeed, mitochondrial depolarization associated with sustained
cytosolic Ca2+ rise causesmitochondrial fragmentation in which DLP1
phosphorylation at Ser637 appears to play a critical role [16,17,22,23].
A more recent study suggested that inhibition of complex II by 3-
nitropropionic acid causes mitochondrial ﬁssion, likely mediated by
increased oxidative stress and nitrosative stress following glutamate
receptor activation of the NMDA subtype, rather than energy deﬁcits
per se [102]. In this regard, it is known that short exposure to low levels
of ROS causes transient changes in themitochondrial morphology and
ﬁne structure by inhibiting both the fusion and ﬁssion processes
throughmodulation of the expression of ﬁssion/fusion proteins [111].
That the balance between mitochondrial ﬁssion and fusion can
signiﬁcantly impact mitochondrial function, and is also rapidly
affected by mitochondrial function, is likely critical for each and
every cell to meet its physiological needs under certain and ever-
changing environment and thus shapes distinctive mitochondrial
network between different cell types. However, changes that exceed
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excessive fusion, likely will cause a downward spiral (or vicious cycle)
that exacerbates mitochondrial dysfunction. Such a downward spiral
appears to play a role in mitochondrial dysfunction in both genetic
factor-induced and mitochondrial toxin-induced neurodegeneration
models, although it is unclear in the former whether genetic factor-
induced dynamics changes or functional changes initiate the cascade.
6.2. mtDNA integrity
One possible mechanism underlying excessive ﬁssion/fusion-
induced mitochondrial dysfunction is through the loss of mtDNA
integrity. mtDNA genome encodes 24 genes that are involved in local
mitochondrial protein synthesis and 13 essential protein subunits of
the OXPHOS complexes I, III, IV and V. Therefore, the integrity of
mtDNA is critical for proper mitochondrial function. Since each
mitochondrion contains 1–10 copies of mtDNA and each cell contains
hundreds of mitochondria, mitochondrial dysfunction and cellular
dysfunction will manifest only after mtDNA defects accumulate to a
certain threshold level. Mitochondrial fusion allows the mixture and
exchange of mitochondrial contents includingmtDNA and its encoded
proteins. This will enable each individual mitochondrion that has
suffered stochastic loss of essential components to rapidly replenish
their stores, thus effectively lowering the effect of defect mtDNA.
Therefore, inhibition of mitochondrial fusion will likely maximize and
exacerbate the effect of defect mtDNA on mitochondrial function.
Indeed, in Mfn2-deﬁcient cells where mitochondrial fusion is entirely
abolished, mitochondrial fragmentation results in a majority of
mitochondria lacking mtDNA [104]. Due to the lack of essential
respiratory subunits encoded by mtDNA, these mitochondria lack
electron transport activity. However, on the other hand, mitochon-
drial fusion that creates a shared compartment of mtDNA may cause
expansion of mtDNA deletion mutants because of their survival
advantage of rapid replication [112]. Indeed, preventing mitochon-
drial ﬁssion by down-regulating expression of DLP1 or Fis1 in
mammalian cells favors the accumulation of mutant mtDNA and
leads to a loss of mtDNA and a decrease of mitochondrial respiration
coupled to an increase in the levels of cellular ROS [105,109,113].
Importantly, mitochondrial ﬁssion, coupled with fusion and followed
by autophagy, allows sequestration and elimination of irreversibly
damaged mitochondria and mitochondrial content, thus maintaining
the integrity and homogeneity of mitochondria population through-
out the cell [114]. Therefore, an altered balance between mitochon-
drial ﬁssion and fusion may affect the removal of damaged mtDNA
and thus contributes to the accumulation of mutant mtDNA. In this
regard, it is notable that accumulation of damaged or mutatedmtDNA
is almost an invariant feature of all these neurodegenerative diseases
[40–42,57,80,82,96,97] and it is likely that abnormal mitochondrial
dynamics is involved.
6.3. Synaptic maintenance
As a specialization for communication, synaptic function and
maintenance are critical for neuronal function and survival. It is
generally accepted that the intracellular distribution of mitochondria
is adapted to and critical for cellular physiology so that mitochondria
concentrate in subcellular regions with high metabolic requirement
[115]. Therefore, it is not surprising that, with the high energy
demand and calcium buffering requirements, synapses are packed
with mitochondria [116,117]. To exert their synaptic roles, mitochon-
dria must be transported from the soma to distal synapses via
cytoskeleton and constantly reconﬁgure to meet synaptic needs [118].
While synapses are more sensitive to declines in mitochondrial
function than soma, due to the considerable length and complex
morphology, they are also much more vulnerable to interruption of
mitochondrial distribution mechanisms. Not surprisingly, deﬁcits inaxonal transport, especially the transport of mitochondria, are
indicated as common themes in neurodegenerative diseases and
some of the genetic factors are implicated in the regulation of
mitochondrial transport. For example, PINK1 is involved in mito-
chondrial trafﬁcking through interaction with Miro and Milton [119],
thus potentially affecting the distribution of mitochondria. Impor-
tantly, mitochondrial dynamics also impact mitochondrial movement
and distribution since both ﬁssionmutants (i.e., DLP1) with elongated
mitochondria [120] and fusion mutants (i.e., OPA1) with short,
rounded mitochondria [121] caused mitochondrial distribution
changes, although the mechanisms involved are not clear. Indeed, in
primary neuronal cultures, perturbation of either mitochondrial
ﬁssion or fusion proteins affected the number of dendritic mitochon-
dria which in turn affected the number and plasticity of spines and
synapses and there is a correlation between dendritic spine
morphogenesis and recruitment of nearby mitochondria [49,122].
ADDLs-induced loss of dendritic spine and PSD95-positive puncta
correlated with reduced dendritic density of mitochondria and can be
prevented by DLP1 overexpression which only restored normal
dendritic mitochondrial density but had no effect on mitochondrial
function [49]. In vivo, DLP1 mutations in Drosophila led to elongated
mitochondria and failure to properly populate the distal axon with
mitochondria [123]. It causes synaptic dysfunction including elevated
basal calcium levels and failure to mobilize reserve pool vesicles
during intense stimulation at neuromuscular junction (NMJ). Neuron-
speciﬁc DLP1-deﬁcient mouse die shortly after birth as a result of
brain hypoplasia with apoptosis. Aggregated mitochondria that failed
to distribute properly within the cell processes correlated with a
decreased number of neurites and defective synapse formation, which
is likely the cause of abnormal forebrain development [124]. Similarly,
cerebellum-speciﬁc Mfn2-deﬁciency causes movement defect and
lethality due to extensive degeneration of Purkinje cells [104].
Although Mfn2-deﬁciency-induced excessive fragmentation which
causes severe mitochondrial dysfunction is thought to play a major
role, Mfn2-deﬁciency aberrant mitochondrial distribution in Purkinje
cells likely also contributes to deﬁcits in dendritic outgrowth, spine
formation, and cell survival. Synaptic dysfunction is arguably the
earliest event in most neurodegenerative diseases causing clinical
symptoms such as memory loss, cognitive decline, and motor
dysfunction and an abnormal mitochondrial dynamics is likely a
contributing factor causing the early manifestation of synaptic
dysfunction via abnormal mitochondrial distribution.
6.4. Cell death
Extensive neuronal death occurs in neurodegenerative diseases
and despite the controversy, apoptosis is implicated. Mitochondrial
dynamics are involved in the regulation of apoptosis with
mitochondrial fragmentation being an early event during apoptosis
that precedes cytochrome c release and caspase activation [125].
Upon apoptotic induction, Bax/Bak-dependent sumoylation and
mitochondrial recruitment of DLP1 increase along with increased
mitochondrial ﬁssion [126]. DLP1 downregulation by RNAi
decreases mitochondrial fragmentation, cytochrome c release,
caspase activation, and cell death [125]. Similarly, the DLP1
inhibitor, mdivi-1, inhibits DLP1 translocation to mitochondria and
mitochondrial ﬁssion and cell death [127]. Mitochondrial fusion was
found to be blocked during apoptosis [128]. Knockdown of Mfn1,
Mfn2, or OPA1 increases the cellular vulnerability to apoptotic
stimuli while overexpression of these fusion proteins renders
resistance [129]. OPA1 also controls apoptotic cristae remodeling
during apoptosis independent of fusion [130,131]. Bcl-2 family
members including Bax, Bak, Bcl-2, and Bcl-xL were found to affect
mitochondrial dynamics and speciﬁcally interact with Mfn1 or Mfn2
which further links mitochondrial dynamics and regulation of
apoptosis [132]. In general, inhibition of ﬁssion reduces apoptosis
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However, apoptosis can occur in the absence of mitochondrial
ﬁssion and excessive mitochondrial ﬁssion may not necessarily
cause apoptosis [61]. Moreover, it was also reported that DLP1-
dependent mitochondrial ﬁssion blocks intraorganellar Ca2+ waves
thereby protecting cells against Ca2+-mediated forms of apoptosis
[107]. Neuron-speciﬁc DLP1-deﬁcient mice die shortly after birth
due to brain hypoplasia with apoptosis [124]. Apparently, further
studies are needed to elucidate the role of mitochondrial ﬁssion and
fusion in the regulation of apoptosis and other types of cell death
and its potential contribution to neurodegeneration.
7. Conclusion
There is no doubt that mitochondrial abnormalities and dysfunc-
tion are involved in neurodegenerative diseases; however, it is still a
matter of debate whether or not such abnormalities are a cause or
merely a consequence—among many—of the diseases. It is also not
clear how mitochondrial abnormalities and dysfunction cause
selective neurodegeneration in different neurodegenerative diseases.
With the deeper understanding of dynamic nature of mitochondria
characterized by a tightly controlled balance of ﬁssion and fusion,
emerging evidence suggests that abnormal mitochondrial dynamics is
involved in various neurodegenerative diseases. Although this recent
development in the ﬁeld will unlikely resolve the debate over a causal
and selective role of mitochondrial dysfunction in neurodegeneration,
given that mitochondrial dynamics signiﬁcantly impacts mitochon-
drial genome integrity and bioenergetics and neuronal functions
including synaptic maintenance and cell death, it is very likely that
abnormal mitochondrial dynamics represents a key common pathway
mediating or amplifying mitochondrial dysfunction and neuronal
dysfunction during the course of neurodegeneration. Therefore,
strategies to modify abnormal mitochondrial dynamics may be an
attractive therapeutic intervention target for the treatment of
neurodegenerative diseases.Acknowledgements
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